Differences in inflammatory response of AML cells in patients with different clinicopathological characteristics and prediction of sensitivity to commonly used chemotherapeutic drugs and immunotherapy response for AML
(A) Clinicopathological features, (B) somatic mutation signatures, (C) therapeutic sensitivity of three commonly used chemotherapeutic drugs for AML. (D) Response prediction to immunotherapy (anti-PD-1 and anti-CTLA4) between the low- and high-inflammatory groups.